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The nucleolus is a stress sensor associated with cell cycle progression and a viral target. However,
the role of the nucleolus during hepatitis B virus infection has not been studied. Here we show that 
under nucleolar stress, the HBx oncoprotein down-regulates p53 and p21 waf1 levels by disrupting 
the interaction between ribosomal protein L11 and MDM2. Further, HBx inhibited Act D-mediated 
down-regulation of proliferat ive factors such as c-Myc and cyclin E and revived RNA pol I-dependent 
transcription under these conditions. Importantly, HBx also countered the action of anticancer drug 
Paclitaxel suggesti ng its possible role in drug resistance. Thus, HBx not only can facilitate cell pro- 
liferation under stress conditions but can confer resistance against anticancer drugs.
Structured summary of protein interactions:
RPL11 physically interacts with HBx and MDM2 by anti bait coimmunoprecipitation (View interaction)
MDM2 physically inter acts with HBx by anti bait coimmunoprecipitation (View interaction)
p53 physically interacts with HBx by anti bait coimmunoprecip itation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ratio. The free pool of RP leaks out of nucleoli and inhibit MDM2 Nucleolus is a non-membranous highly organised sub nuclear 
structure that is the seat of ribosomal RNA (rRNA) transcriptio n
and hub of ribosome biogenesis [1]. More recently, nucleolus is 
being linked to stress sensing and control of cell cycle progression 
[2,3]. Activation of p53–MDM2 regulatory loop by ribosomal pro- 
teins (RPs) plays an important role in mediating nucleolar stress 
and imposes cell cycle arrest and apoptosis . Nucleolar/ri bosomal 
stress induced by diverse means such as overexpres sion or knock 
down of nucleolar proteins, treatment with actinomycin D (Act
D) or anisomysin, serum starvation and contact inhibition [2–4]
are reported to induce sequestration of MDM2 and inhibition of 
its ubiquitin ligase activity against p53 [1,5]. Importantly, RPs such 
as RPL11, RPL5 and RPS27a also help in maintaining a balance be- 
tween rRNA transcriptio n and ribosome biogenesis. Conditions 
that halt rRNA transcription also lead to imbalance in rRNA/RP activity leading to stabilisation of p53 and stalling of cell prolifer- 
ation [5].
Nucleolu s is a potent target of viral infections [4,6]. All DNA,
RNA as well as retro-viru ses have evolved mechanism s to over- 
come the nucleolar stress response that seems to give survival 
advantag e to the infected cells by averting clearance by the host 
immune system [6]. Further, this allows viruses to complete 
their life cycle [7]. The HBx protein of hepatitis B virus (HBV)
has been linked with hepatocyte’s ability to overcome various 
stress and facilitate cell cycle progression [8]. However , the exact 
mechanis m employed by HBx to counter stress response still re- 
mains elusive. Today drug resistance in cancer therapy remains a
major public health problem [9]. In this regard, constant ly evolv- 
ing nature of viruses owing to their error prone polymerase of- 
ten makes drug therapy a failure due to emergence of viral 
strains. This is further complicated by the presence of viral 
structura l or regulator y proteins that can confer resistance to 
both anti-viral and anti-cancer drugs which makes the removal 
of affected cells difﬁcult [10,11]. Problems of drug resistance in 
the HBV-related tumours have been reported [12] but the molec- 
ular mechanism behind it still remains unexplained. Here, we 
show that viral HBx can inhibit p53 activation mechanisms in 
cells under nucleolar stress or during treatment with anti-cancer 
agents. Further, we expedite the role of HBx in conferring drug 
resistance to HBV infected cells.
Fig. 1. Levels of c-myc under nucleolar stress. (A) IHH cells transfected either with 
control or HBx expression vectors were treated with DMSO or 5 nM Act D and 
analysed for c-myc mRNA levels by RT-qPCR. The Ct values were normalised against 
GAPDH. (B) HepG2 or HepG2.2.15 cells were either treated with DMSO (lanes 1 and 
3) or 5 nM Act D (lanes 2 and 4) followed by WB for c-Myc. ⁄Statistically signiﬁcant
at P < 0.05.
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2.1. Cell culture and transfection 
The immortal ised human hepatocytes (IHH) were kindly pro- 
vided by F. Danniel, while HepG2.2.15 cells were gift from Dr. S.
Kamili. HepG2 (HB-8065) were procured from ATCC, USA. Huh7 
and other cells were maintained and transfected as described ear- 
lier [13].
2.2. Plasmids chemicals and antibodies 
HBx expression vector was described earlier [13]. Flag tagged 
RPL11 construct was a kind gift from K. Vousden [14]. All antibod- 
ies were procured from Santa Cruz Biotechnolo gies (USA). Act D,
Paclitaxel and Doxorubicin were from Sigma Aldrich (USA). Drugs 
were added 24 h post transfection at a concentr ation of 5 nM for 
next 24 h.
2.3. RNA isolation and RT-qPCR 
Total RNA isolation, reverse transcrip tion and RT-qPCR have 
been described previously [15]. Acidic ribosomal phospho protein 
P0 (ARPP) or GAPDH were used as internal control for pol I and 
Pol II transcripts respectively. Analysis was performed with the 
DDCt method [15]. Primer list is given in Supplement ary Table S1 .
2.4. Western blot and immunoprec ipitation 
Cells were lysed in lysis buffer (Cell Signaling Technology , MA)
and immunoprecip itated or western blotted as described earlier 
[13]. The protein band intensities were determined by densitome- 
try using NIH ImageJ software.
2.5. Determinati on of protein half-life 
The Cells grown in 60 mm plates and treated with DMSO or 
5 nM Act D for 16 h followed by treatment with protein translation 
inhibitor, cycloheximi de (CHX) (30 lg/ml) in the continued pres- 
ence of DMSO or Act D. Cell extracts were analysed by Western 
blotting.
2.6. Statistical analysis 
The statistical signiﬁcance of results was calculated with Stu- 
dent’s t-test. A P-value of <0.05 was considered to be signiﬁcant.
3. Results 
3.1. HBx inhibits down-regula tion of c-myc mRNA levels under 
nucleolar stress 
Ribosomal proteins (RP) are crucial regulators of nucleolar 
stress induced p53 activation. Nucleolar stress leads to leakage of 
RP from nucleolus where they activate important checkpoints.
RPL11 interacts and inhibits the function of c-Myc, transcriptio n
factor during rRNA transcrip tion [16]. RPL11 can also destabili se 
c-myc mRNA by recruiting ago2-miRNA complexes to c-myc 30
UTR [17]. Therefore, we checked c-myc mRNA levels in cells under 
HBx microenvironmen t. IHH cells treated with Act D were checked 
for c-myc mRNA levels by RT-qPCR. Act D treatment led to a signif- 
icant reduction (P < 0.05) in the transcrip t levels as compared to 
control. However , the repressive effect of Act D on c- myc tran-
scripts was abrogated in the presence of HBx (Fig. 1A) which would 
otherwise elicit apoptotic response and translate nucleolar stress into cell cycle arrest. HBx alone only marginall y increased c-myc
mRNA levels. To evaluate the RPL11 in these conditions, we over- 
expresse d RPL11 in the absence or presence of Act D. As expected,
this led to a signiﬁcant reduction in the levels of c-myc transcrip ts 
like the control cells treated with Act D (Supplementary Fig. S1 ).
We also checked the c-Myc protein levels in HepG2.2.15 cells that 
constituti vely expresses HBx gene. c-Myc levels remained unal- 
tered in HepG2.2.15 cells upon Act D treatment but declined in 
HepG2 cells (Fig. 1B). Thus, the presence of HBx seems to confer 
resistance to nucleolar stress.
3.2. HBx interferes with stabilization of p53 under nucleolar stress 
To understand the mechanism of HBx-depend ent nucleolar 
stress response, we checked levels of key cell cycle regulator 
protein p53. The Act D-treated HepG2.2.15 cells showed low levels 
of p53 while HepG2 cells exhibited p53 accumulation (Fig. 2A).
Under these condition s, MDM2 levels were higher in HepG2.2.15.
Since, the post-transla tional modiﬁcations of MDM2 is well known 
to regulate its intracellul ar localisation, stability and activity [18],
we next checked the phosphoryla tion status of MDM2. Decrease d
levels of pMDM2 (Thr-218) in HepG2.2.15 cells as compare d to 
HepG2 cells suggested a sustained interaction with p53 in 
HepG2.2.15. Since, MDM2 is also a transcrip tional target of p53,
its accumulation under nucleolar stress was indicative of a
post-trans criptional regulatory mechanis m operational in 
HepG2.2.15 cells. Next we compare d the stability of p53 and 
MDM2 in these cells. There was a marked increase in stability of 
Fig. 2. Stability of p53 under nucleolar stress. (A) HepG2 or HepG2.2.15 cells were either treated with DMSO or Act D. The cell lysates were WB with indicated antibodies.
GAPDH served as internal control. (B) Act D-treated HepG2 or HepG2.2.15 cells were treated with CHX for indicated time periods and analysed by WB. IHH cells transfected 
either with vector or HBx were treated with DMSO or 5 nM Act D. Lysates were analysed by WB for p53 (C) or by RT-qPCR for p21 (D) and cyclin E levels (E). GAPDH served as 
internal control. Arrows indicate the position of p53. ⁄Statistically signiﬁcant at P < 0.05.
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<30 min in HepG2 cells (Fig. 2B). p53 was however, more unstable 
(half-life = 30 min) in HepG2.2.15 cells as compare d to HepG2 
cells suggesting the existence of a post-translatio nal mechanism 
in HepG2.2.15 possibly involving RPL11–MDM2 pathway. These 
observations could be substanti ated in HBx-transfected cells that 
showed p53 accumulati on in control cells under nucleolar stress 
but no change in HBx expressing cells (Fig. 2C). Therefore, HBx 
inaction in the absence of any nucleolar stress is an indicator that 
its oncogenic potential unfolds better under stress conditions.
To further understand HBx role in p53 destabilisation and its 
effect on cell cycle, the mRNA levels of key cell cycle regulators 
p21waf1 and cyclin E were measured by RT-qPCR. A signiﬁcant
10-fold increase in the level of p21 waf1 transcripts was observed 
after Act D treatment which was dramatically reversed in the pres- 
ence of HBx (Fig. 2D). In contrast, the cyclin E levels which indicate 
G1/S phase transition were down-regul ated under stress condition but were restored in the presence of HBx (Fig. 2E). These results 
suggested the abrogation of negative cell cycle regulator y mecha- 
nisms under HBx microenvironmen t.
3.3. HBx interacts with MDM2 and interferes with RP-mediated p53 
activation under nucleolar stress 
To delineate the mechanism employed by HBx to overcome 
nucleolar stress, we next investigated its interactions with 
RPL11–MDM2–p53 regulatory axis. As reported earlier [19], we 
also observed a strong interaction between HBx and MDM2 which 
considerably increased upon Act D treatment. Further, as shown 
earlier [20], HBx showed poor interaction with p53 under normal 
condition s but this increased by nearly 10-fold under nucleolar 
stress (Fig. 3). Since RPL11 moves out of nucleolus under nucleolar 
stress to bind and sequester MDM2 and stabilize p53 [1], we won- 
dered if HBx interfered with RPL11-de pendent MDM2 regulatio n.
Fig. 3. Conditional interactions of HBx with p53 and MDM2. IHH cells either 
transfected with empty vector or HBx and treated with DMSO (lanes 1 and 2) or 
5 nM Act D (lanes 3 and 4). The cell extracts were analysed by IP using MDM2, p53 
or RPL11 antibodies followed by WB with antibodies indicated on the right side.
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was observed after Act D treatment which diminished consider- 
ably in the presence of HBx. These data suggested that HBx 
disrupts RPL11–MDM2 interaction under nucleolar stress.
3.4. HBx confers resistance to nucleolar stress by stimulating RNA pol 
I-dependent transcripti on 
The nucleolar stress is also associate d with imbalanc e in the RP/ 
rRNA ratio and arrest of pol I-dependen t transcription leading to 
p53-dependen t arrest of cell cycle [3]. Therefore, we measured 
RNA pol I-dependen t transcription under these condition s in the 
presence of HBx. While treatment with Act D resulted in a signiﬁ-
cant decrease (P < 0.05) in the 18s and 28s rRNA levels, co-expres- 
sion of HBx resisted the down-regul ation (Fig. 4). These results 
suggested that HBx could reverse pol I-dependen t transcrip tion 
and abrogate RP-led cell cycle arrest.
3.5. HBx inhibits p53 signalling in paclitaxel treated cells 
Since the preceding results suggested interference of HBx in the 
RPL11–MDM2–p53 regulatory axis, we wondered if viral HBx in 
anyway was involved in drug resistance. We selected two common Fig. 4. Regulation of pol I transcription under nucleolar stress. IHH cells transfected 
either with empty vector or HBx and treated either with DMSO or 5 nM Act D. The 
levels of 18s (A) and 28s (B) rRNA was quantiﬁed by RT-qPCR and normalised 
against ARPP mRNA levels. ⁄Statistically signiﬁcant at P < 0.05.anticance r drugs viz., Paclitaxel, a known mitotic inhibitor [21] and
Doxorub icin, a DNA intercalating agent and inhibitor of Topoi- 
somerases II [22] – both well known to induce p53 levels in cells.
As shown in Fig. 5A, the paclitaxel -treated cells showed a signiﬁ-
cant 6-fold increase in p53 levels in control cells whereas its levels 
were lower (3-fold) under HBx microenvironmen t. Further, no 
appreciabl e change in p53 level was evident in HepG2.2.15 cells 
after Paclitaxel treatment (Fig. 5B). Interestin gly, analysis of p53 
phospho rylation suggested down-regul ation of both Ser-392 and 
Ser-15 under these conditions (Fig. 5C). Nevertheles s, a speciﬁc
accumulati on of MDM2 in the presence of HBx (Fig. 5A) and 
down-re gulation of phosphorylated MDM2 in HepG2.2.15 cells 
were observed as compared to HepG2 cells (Fig. 5B) indicating sus- 
tained MDM2–p53 interactio n under HBx microenvironm ent. No 
appreciabl e change in the levels of p53, MDM2 or pMDM2 was evi- 
dent in the presence of HBx after doxorubicin treatment indicating 
speciﬁcity of viral HBx in conferrin g resistance to certain class of 
drugs. Thus, the viral HBx protein may have a role in drug 
resistance.
4. Discussion 
Nucleolu s has emerged as a prime stress sensor of the cell capa- 
ble of activating cell cycle checkpoints in response under adverse 
condition s [2,3]. Perturbati ons in the nucleolar organisation or 
functions by viruses lead to reduced apoptosis , enhanced cell cycle 
progression and immune evasion. This allows viruses to hijack the 
host machiner y to complete their life cycle [4,6]. The HBx protein 
of HBV is reported to employ multitude of mechanism s to force in- 
fected host cells to proliferate [8]. However, the involvem ent of 
nucleolus during HBV infection is not studied. Further, persistent 
problem of drug resistance in anticance r/antiviral therapies 
prompted us to investiga te the role of HBx in the treatment of 
HCC. Here we provide new evidences suggesting HBx interference 
in cellular checkpoints that are normally activated during nucleo- 
lar stress.
To support our hypothesis, we ﬁrst checked the expression of c-
myc under nucleolar stress. c-Myc is considered important for the 
coordina ted transcrip tion of pol I, II and III-depende nt promoters 
and optimal protein translation [23]. Under these condition s, HBx 
rescued both c-myc mRNAs and protein levels (Fig. 1) suggesting 
a novel mechanis m underutilise d by HBx to maintain intracellul ar 
c-Myc level. Earlier, we reported that HBx can stabilize c-Myc lev- 
els by preventing its proteasomal degradation [13]. We also found 
that HBx can facilitate RNA pol I-dependen t transcriptio n that 
seems to be helpful in maintaining RP/rRNA ratio even under 
nucleolar stress (Fig. 4) by collating signals in the cell and guiding 
the rRNA transcrip tional machinery for optimal ribosome biogene- 
sis [15,28].
The 60s ribosomal protein RPL 11 has been reported to regulate 
MDM2 onco-pro tein and activate p53-dependen t ribosomal -stress 
checkpoi nt pathway by binding and sequesterin g the MDM2 pro- 
tein to ensure p53 stabilisation and activity [1,3]. We found that 
under nucleolar stress and HBx microenvironm ent, the interaction 
between RPL11 and MDM2 is disrupted but the HBx–MDM2 inter- 
action is favoured (Fig. 3). On contrary, the HBx–p53 interaction 
which is weak under normal conditions, increased signiﬁcantly
(by 10-fold) under nucleolar stress. As HBx interacts with 
MDM2, we speculate that this interaction might help in bringing 
MDM2 in close proximity of p53 to destabilise it. In fact a condi- 
tional HBx–p53 interaction has been reported recently which 
shows that HBx can differentially modulate p53-dependen t apop- 
tosis in normal and tumour cells [27].
RPs are also reported to perform extra ribosomal functions and 
activate p53-dependen t cell cycle check points and thus, provides a
Fig. 5. Regulation of p53 in the presence of mitotic inhibitor. Huh7 cells transfected either with empty vector or HBx (A and C) or HepG2 and HepG2.2.15 cells (B) were 
treated with DMSO, 5 nM paclitaxel or 5 nM Doxorubicin for 24 h. Equal amount of extracts were WB with indicated antibodies. GAPDH served as internal control. Arrow 
indicates the position of p53.
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example, RPL11 shuttles to cytoplasm from the nucleolus following 
disruption of rRNA transcriptio n and cooperates with ago2 for 
binding to the 3’UTR of c-myc mRNA and its degradation [16,17].
However, HBx seems to interfere with Act D-mediated destabili sa- 
tion of c-myc mRNA (Fig. 1). The interfere nce of HBx in the 
RP–MDM2–p53 regulator y loop was further substantiated by its 
effect on key regulators of cell cycle, viz., p21 waf1 a direct transcrip- 
tional target of p53 and cyclin E. As expected, the down-regulati on 
of p53 levels (Fig. 2A and C) was also associate d with down-regu- 
lation of p21 waf1 (Fig. 2D). In contrast, cyclin E mRNA levels were 
not down-regul ated in presence of HBx substantiati ng its role in 
cell proliferation (Fig. 2E).
We also observed a blockade in p53 signalling under nucleolar 
stress and HBx microenvironmen t due to stabilization of p53 
destructor MDM2 (Fig. 2A and B). Note that increased MDM2 level 
is a salient feature of tumour cells that allows uncontrolled cell 
proliferation due to low levels of p53 [25]. Further, MDM2 accumu- 
lation in tumour tissue is known to be associate d with MDM2 gene 
ampliﬁcation, increased MDM2 stability and inactivation of p53 
[26]. This was also substantiated by a reduction in MDM2 phos- 
phorylation (Fig. 3B) which is an indicator of sustained 
p53–MDM2 interaction.
Drug resistance is a common problem encounter ed during the 
treatment of many infectious and chronic diseases [28,29]. Liver- 
associated diseases are essentially managed by palliative treat- 
ment [30]. We wondered if patients having genetic integration of 
HBx gene (the incidence is >80% cases of HBV infection) would 
respond different ly to anti-cancer therapy. In fact, HBV is reported 
to induce multidru g resistance by upregulating Calreticu lin [31]
and NF- jB [32]. Since HBx is a multifunctional protein implicated 
in cell transformation and carcinogenesis , we probed its ability to 
confer drug resistance to affected cells by interfering with p53 acti- 
vation pathways thereby giving these cells a clonal advantage. Our 
data strongly suggested that HBx can suppress Paclitaxe l-induced 
p53 signalling with a concomitan t increase in MDM2 and decrease 
in pMDM2 levels (Fig. 5A and B). Further, a marked inhibition in p53 phospho rylation in paclitaxel-trea ted cells in presence of 
HBx, indicated loss of p53 functions (Fig. 5C). In contrast, Doxoru- 
bicin did not show a such effect. This may be attributed to different 
mode of action of these two drugs and speciﬁcity of HBx in coun- 
tering the pharmacolo gical effects of paclitaxel. Thus, a viral factor 
like HBx seems to have a role in drug resistance which may inﬂu-
ence the outcome of HCC therapy.
Based on the above ﬁndings, we propose that HBx plays a cen- 
tral regulator in determining the fate of cells exposed to nucleo- 
lar stress induced by chemicals and/or overexpression of other 
regulator y molecules. This could avert the cellular checkpoi nts 
and allow cell cycle progression even under stress condition s
and allow viral replication to continue. Such anti-apopto tic func- 
tion of HBx may be providing clonal advantage to virus-inf ected 
cells and giving way to multistep carcinogene sis. Sadly, the sur- 
vival advantage provided by viral HBx is appeared to be a curse 
in disguise since HBx also conferred resistance to anticancer ther- 
apy by targeting RNA pol I-dependen t transcription [28,29]. Our 
data opens up a new avenue where the role of HBx in virus life 
cycle, hepatitis B pathophysiology and antiviral/an ticancer ther- 
apy can be revisited from the point of nucleolus as prime stress 
sensor.
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